Trial Profile
A Multicentre, Randomised, Double-blind, Placebo-Controlled Phase 3 Extension Study to Characterise the Long-term Safety and Tolerability of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Jan 2024
Price :
$35
*
At a glance
- Drugs Anifrolumab (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions; Registrational
- Acronyms TULIP SLE LTE
- Sponsors AstraZeneca; AstraZeneca AB
- 15 Nov 2023 Results reporting long-term outcomes; total and organ-specific disease activity over 4 years presented at the ACR Convergence 2023
- 15 Nov 2023 Results of post hoc analysis assessing renal outcomes in patients with Systemic Lupus Erythematosus with or without evidence of SLEDAI-2K renal involvement at baseline, were presented at the ACR Convergence 2023.
- 15 Nov 2023 Results of post hoc analysis of long-term impact of anifrolumab treatment on the Short Form 36 Health Survey version 2 (SF-36v2) in patients receiving standard therapy , presented at the ACR Convergence 2023